Sante(002159) Yin He Zheng Quan·2025-04-09 15:35Investment Rating - The report maintains the investment rating for the company [3] Core Views - The company is projected to experience revenue growth from 692.47 million in 2024 to 907.42 million in 2027, reflecting a compound annual growth rate (CAGR) of approximately 9.70% [8] - The net profit is expected to increase from 164.35 million in 2024 to 251.43 million in 2027, indicating a growth rate of 8.79% [8] - The EBITDA is forecasted to rise from 350.56 million in 2024 to 449.14 million in 2027, showing a steady increase in operational profitability [8] Financial Summary - The total assets are projected to grow from 1851.25 million in 2024 to 3340.40 million in 2027 [7] - The company's total liabilities are expected to increase from 437.22 million in 2024 to 1236.15 million in 2027 [7] - The return on equity (ROE) is anticipated to be 10.40% in 2024, peaking at 12.05% in 2025, and then gradually declining to 11.28% by 2027 [8] - The company’s cash flow from operating activities is estimated to rise from 285.28 million in 2024 to 406.66 million in 2027 [7] Key Financial Ratios - The gross margin is projected to improve from 60.34% in 2024 to 63.60% in 2027 [8] - The net profit margin is expected to increase from 20.50% in 2024 to 24.62% in 2027 [8] - The price-to-earnings (P/E) ratio is forecasted to decrease from 18.63 in 2024 to 11.84 in 2027, indicating potential undervaluation over time [8]